Tranexamic acid targets underlying erythema in melasma

A first RCT of oral tranexamic acid for the management of patients with melasma has found twice daily treatment reduces lesional erythema. A small Melbourne study randomised 17 patients with moderate to severe melasma to either oral tranexamic acid (25mg twice daily) or placebo for 12 weeks. All patients also applied daily SPF 50+ sunscreen ...

Already a member?

Login to keep reading.

© 2021 the limbic